ADC Therapeutics S.A.
ADCT
NYSE·Healthcare·Biotechnology·Mkt cap $173.0M
$1.36
▲ +3.03%
P/E
-2.05
Mkt Cap
$173.0M
52-Wk Range
$0.78–$4.98
52-Week Range
$0.78 - $4.98
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Down 61.4% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
5 reasons
- Proprietary ADC technology platform with optimized linker and payload design
- Strategic partnerships with major pharmaceutical companies (Genmab, MedImmune, Mitsubishi Tanabe Pharma)
- Advanced clinical pipeline with multiple candidates in Phase II/III trials
- Experienced management team with deep oncology and biotechnology expertise
- Synaffix collaboration providing access to next-generation linker technology
Bear Case
1 risk
- Above-average volatility (beta 1.8).
Growth
Stable outlook
Steady revenue growth (15% YoY)
Value
Deep value opportunity - significant discount to Biotech & Therapeutics peers
Momentum
Hot
+39.1% over 3m
Quality
Excellent
Solid business
Dividend
None
No dividend
Smart-money signal
Who's buying ADCT right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Latest print - beat on both lines
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Nov 10, 2026
AUG 13, 2026
Reported EPS of -$0.11 vs -$0.22 consensus (+49.1% surprise). Revenue of $19.2M vs $18.9M expected (+1.9%). Beat on both top and bottom lines.
EPS surprise · last 4Q
1 of 1 beats
Estimate
Actual
Q3 26
+49.1%
Revenue trend · last 8Q
—
+1%
+28%
+8%
-11%
+36%
-9%
-1%
Q3 24
Q4 24
Q1 25
Q2 25
Q3 25
Q4 25
Q1 26
Q2 26
$18.5M
$16.9M
$23.0M
$18.8M
$16.4M
$23.1M
$20.9M
$18.6M
Margins · last 8Q
Gross
87.4%
Operating
-136.4%
Profit
-88.9%
Wall Street consensus
4 analysts · 50% Buy
Live ratings and price targets aggregated across covering analysts.
Buy
50%
Hold
50%
Sell
0%
Median Price Target
—
Latest: HC Wainwright · Jun 8, 2026
vs Industry
How ADCT stacks vs Biotechnology
Stock metrics vs industry averages. Green = better than industry.
Industry comparison data unavailable for this stock.
Related